Abstract
In about 48% hypertensive patients in the United States, blood pressure remains higher than accepted treatment targets despite broad availability of effective pharmaceutical agents. Of these 48%, recent estimates define about 10-11% have treatment-resistant hypertension (TR-HTN). Compensatory changes in sympathetic nervous system function are an important component of HTN. Recent technical advances targeting the sympathetic activity of the carotid sinuses (Baroreflex Activation Therapy-BAT) and the renal sympathetic nerves (Renal Denervation Therapy-RDT) have renewed interest in invasive therapy for the treatment of drug-resistant hypertension. Encouraging results from the recent Rheos Pivotal and Symplicity HTN-2 trials on the safety and efficacy of BAT and RDT respectively, indicate that invasive approaches can safely reduce blood pressure in patients with resistant hypertension. The main goal of this article is to review the results of preclinical and clinical studies on the electric stimulation of the carotid sinus and the catheter-based renal denervation.
Keywords: Resistant hypertension, baroreflex activation therapy, renal sympathetic denervation.
Current Vascular Pharmacology
Title:The Future of Interventional Management of Hypertension: Threats and Opportunities
Volume: 12 Issue: 1
Author(s): Alexandros Briasoulis and George Bakris
Affiliation:
Keywords: Resistant hypertension, baroreflex activation therapy, renal sympathetic denervation.
Abstract: In about 48% hypertensive patients in the United States, blood pressure remains higher than accepted treatment targets despite broad availability of effective pharmaceutical agents. Of these 48%, recent estimates define about 10-11% have treatment-resistant hypertension (TR-HTN). Compensatory changes in sympathetic nervous system function are an important component of HTN. Recent technical advances targeting the sympathetic activity of the carotid sinuses (Baroreflex Activation Therapy-BAT) and the renal sympathetic nerves (Renal Denervation Therapy-RDT) have renewed interest in invasive therapy for the treatment of drug-resistant hypertension. Encouraging results from the recent Rheos Pivotal and Symplicity HTN-2 trials on the safety and efficacy of BAT and RDT respectively, indicate that invasive approaches can safely reduce blood pressure in patients with resistant hypertension. The main goal of this article is to review the results of preclinical and clinical studies on the electric stimulation of the carotid sinus and the catheter-based renal denervation.
Export Options
About this article
Cite this article as:
Briasoulis Alexandros and Bakris George, The Future of Interventional Management of Hypertension: Threats and Opportunities, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/15701611113119990137
DOI https://dx.doi.org/10.2174/15701611113119990137 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute Actions of Natriuretic Peptides in Coronary Vasculature and Ischaemic Myocardium
Current Pharmaceutical Design Ghrelin and Growth Hormone Secretagogues, Physiological and Pharmacological Aspect
Current Drug Discovery Technologies Editorial (Thematic Issue: Disease Control and Active and Healthy Ageing: New Paradigms of Therapeutic Strategy)
Current Pharmaceutical Design Sustained ELABELA Gene Therapy in High-salt Diet-induced Hypertensive Rats
Current Gene Therapy Granulocyte Colony-Stimulating Factor Attenuates Blood-Brain Barrier Damage and Improves Cognitive Function in Spontaneously Hypertensive Rats
CNS & Neurological Disorders - Drug Targets Targets Involved in Cardioprotection by the Non-Anesthetic Noble Gas Helium
Current Drug Targets Metabolic Syndrome and Its Effect on the Brain: Possible Mechanism
CNS & Neurological Disorders - Drug Targets Microglial Activation with Reduction in Autophagy Limits White Matter Lesions and Improves Cognitive Defects During Cerebral Hypoperfusion
Current Neurovascular Research The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Targeting microRNAs in Pathological Hypertrophy and Cardiac Failure
Mini-Reviews in Medicinal Chemistry Target Based Drug Design - A Reality in Virtual Sphere
Current Medicinal Chemistry Renoprotection with Anti-Hypertensives: Reduction of Proteinuria and Improvement of Oxygenation via Inhibition of the Renin-Angiotensin System
Current Hypertension Reviews The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Interactions of Endothelin and Insulin: Expanding Parameters of Insulin Resistance
Current Diabetes Reviews Global Cardiovascular Risk Management in Primary Prevention
Current Vascular Pharmacology Novel Risk Factors Related to Stable Angina
Current Pharmaceutical Design Premature Adrenarche and its Association with Cardiovascular Risk in Females
Current Pharmaceutical Design ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets The Stable Isotope Use in the Exploration of Bioavailability and Metabolism of Magnesium
Current Nutrition & Food Science